Navigation Links
Short-Term Drug Combo May Help Prevent Colon Cancer
Date:3/29/2010

Lab research finds only precancerous tissue affected, but more study needed

MONDAY, March 29 (HealthDay News) -- A two-drug combination that kills precancerous colon polyps without harming normal tissue offers a potential new way to prevent colon cancer, researchers say.

The combination of vitamin A acetate (RAc) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) was effective in mice and in human colon cancer tissue in the lab, according to the results of a study published online March 28 in the journal Nature.

The treatment appears to solve a problem with current chemopreventive drugs, which is that they must be taken continuously and long term to be effective, thus exposing patients to possible side effects, said study senior author Xiangwei Wu, an associate professor in the head and neck surgery department at the University of Texas M.D. Anderson Cancer Center.

"This combination can be given short term and periodically to provide a long-term effect, which would be a new approach to chemoprevention," Wu said in a university news release.

However, further research is needed before this combination treatment can be considered for human clinical trials, Wu said.

More information

The U.S. National Institute of Diabetes and Digestive and Kidney Diseases has more about colon polyps.



-- Robert Preidt



SOURCE: University of Texas M.D. Anderson Cancer Center, news release, March 28, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Page: 1

Related medicine news :

1. Los Angeles Jewish Home Adds Short-Term Rehabilitative Care to Family of Services
2. WHI data confirm short-term heart disease risks of combination menopausal hormone therapy
3. Short-term radiation therapy successful on breast cancer
4. SNM calls Congress passage of fix for sustainable growth rate a short-term solution
5. Drug Combo Blocks HIV Infection in Mice
6. Combo PET-CT Scans Can Spot Hidden Cancers
7. Blood Thinner Combos Risky for Heart Attack Patients
8. OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent
9. Preventive Mastectomy May Not Lower Risks
10. Targeting cell pathway may prevent relapse of leukemia
11. Octreotide acetate does not prevent treatment-induced diarrhea in anorectal cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... The American ... Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium ... 8. , In honor of Morris F. Collen, a pioneer in the field of ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare events ... Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the ... The annual award competition recognizes editorial and design excellence across a range of sectors. ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health & ... by Moonlight to raise money for the American Heart Association Heart Walk. Teams of ... will work together to keep their treadmills moving for 5 hours. Treadmills will start ...
(Date:10/12/2017)... ... 2017 , ... Health Literacy Innovations (HLI), creator of the ... the Cancer Patient Education Network (CPEN), an independent professional organization that shares best ... alliance. , As CPEN’s strategic partner, HLI will help support CPEN members ...
Breaking Medicine News(10 mins):
(Date:9/19/2017)... ARBOR, Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device ... precise destruction of targeted tissues, announced three leadership team developments today:   ... Stopek, PhD ... ... Veteran medical device executive ...
(Date:9/18/2017)... , Sept. 18, 2017 EpiVax, ... of bioinformatics and immune engineering, today announced ... influenza A (H7N9) vaccine. ... to seasonal influenza and presents a challenge ... prior exposure to be effective. Using state-of-the-art ...
(Date:9/12/2017)... N.J. , Sept. 12, 2017  Consumer reviews on the ... Hearing as the number one company for hearing aids, ranking ... and fifteen other brands. ... Embrace Hearing Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that provides high ...
Breaking Medicine Technology: